Novavax coronavirus vaccine induces immune response in early study, shares jump
WASHINGTON (REUTERS) - Novavax Inc said on Tuesday (Aug 4) its experimental Covid-19 vaccine produced high levels of antibodies against the novel coronavirus, according to initial data from a small, early-stage clinical trial, sending the company's shares up 10 per cent.. Read more at straitstimes.com.
The company said it could start a large pivotal Phase III trial as soon as late September, and on a conference call added that it could produce 1 billion to 2 billion doses of the vaccine in 2021.Novavax research chief Gregory Glenn told Reuters the late-stage clinical trial could potentially glean enough data to obtain regulatory approvals as early as December.
Maryland-based Novavax said its vaccine candidate, NVX-CoV2373, produced higher levels of the antibodies in healthy volunteers after two doses than those found in recovered Covid-19 patients, raising hopes for its eventual success.The addition of the company's Matrix-M adjuvant, a substance designed to boost the body's immune response, did enhance the effect of the vaccine in the study, the company said.
The Novavax vaccine is among the first of a handful of programs singled out for US funding under Operation Warp Speed, the White House program to accelerate access to vaccines and treatments that can fight the virus.Effective vaccines and treatments are considered essential to halting a pandemic that has claimed more than 695,000 lives worldwide. headtopics.com
Novavax's vaccine contains synthesised pieces of the surface protein that the coronavirus uses to invade human cells, spurring production of antibodies to fight the infection.The US government in July agreed to pay Novavax US$1.6 billion (S$2.2 billion) to help cover costs related to testing and manufacturing the vaccine, with the aim of procuring 100 million doses by January 2021.
The trial, which started in late May, tested the vaccine in 106 subjects aged 18 to 59 versus a placebo. The Phase I study looked at the vaccine's safety and ability to induce immune responses.It tested 5 microgram and 25 microgram doses of the vaccine, with and without the adjuvant. The company said it would likely move forward with the lower dose.
Eight study participants experienced adverse side effects after receiving a second vaccine dose during the trial, although none required medical intervention, the company said.Headache, fatigue, and muscle pain were among the more common side effects, and the vaccine was"well tolerated"overall, the company said.
Because Covid-19 vaccines are being developed at unprecedented speed, safety issues are being watched very closely."When you are talking about vaccinating the entire world, safety is almost more important than efficacy," said Brad Loncar, chief executive of Loncar Investments, an investment fund specialising in biotechnology companies. headtopics.com
1.8 million people have received at least one dose of COVID-19 vaccine: Health minister
A total of 1.2 million people have completed the full vaccination regimen, says Mr Gan Kim Yong.
Hermes sales plunge 42 per cent amid global coronavirus store closuresEven the Birkin bag maker isn’t immune to effects of pandemic-induced lockdowns.
Scientists worry about political influence over coronavirus vaccine projectWASHINGTON (NYTIMES) - In April, with hospitals overwhelmed and much of the United States in lockdown, the Department of Health and Human Services produced a presentation for the White House arguing that rapid development of a coronavirus vaccine was the best hope to control the pandemic.. Read more at straitstimes.com.
Coronavirus vaccine confronts humanity with next moral testNEW YORK (BLOOMBERG) - The coronavirus pandemic has stress-tested the world.. Read more at straitstimes.com.
Indonesia eyes production of 250 million doses a year of coronavirus vaccineJAKARTA (REUTERS) - Indonesia will have capacity to produce 250 million doses a year of a coronavirus vaccine by the end of 2020 pending trials on humans, a minister said on Tuesday (Aug 4), as the country seeks to halt a wave of infections that has shown no sign of slowing.. Read more at straitstimes.com.
Indonesia to have capacity to produce 250 million doses of COVID-19 vaccine a yearJAKARTA: Indonesia will have capacity to produce 250 million doses a year of a coronavirus vaccine by the end of 2020 pending trials on humans, a ...
Russia aims to produce 'millions' of COVID-19 vaccine doses by 2021Russia said Monday it aims to launch mass production of a coronavirus vaccine next month and turn out 'several million' doses per month by next year.